Catch up on the latest news, innovation and thought leadership from Roche Diagnostics.
Roche in the news
CAP Today
May 3, 2024
Digital Pathology mini-Roundtable
Is digital pathology on the move? Two who know it well say it is. Esther Abels, a precision medicine and biomedical regulatory health science expert who is CEO of SolarisRTC and former president of the Digital Pathology Association, and Michael Rivers, vice president/lifecycle leader of digital pathology at Roche Tissue Diagnostics, spoke in September with CAP TODAY publisher Bob McGonnagle, who got their take on where things stand.
Medical Laboratory Observer
April 22, 2024
2024 lab management best practices trend back to the basics
The results of the 2024 Medical Laboratory Observer (MLO) State of the Industry (SOI) Survey on Lab Management Best Practices reveal how many lab professionals are turning to fundamental practices and priorities to make operational, clinical and financial improvements – from a focus on staff career development to strengthening supplier relationships.
MedTech Dive
April 12, 2024
Roche scores FDA breakthrough status for Alzheimer’s blood test
Roche has received the Food and Drug Administration’s breakthrough device designation for a blood test to support earlier diagnosis of Alzheimer’s disease, the Swiss drug and diagnostics company said Thursday. The test, once approved, could help healthcare providers identify whether amyloid pathology, a marker for Alzheimer’s disease, is present or absent in patients. The Elecsys pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly.
Contemporary OBGYN
April 3, 2024
Enhancing cervical cancer management with dual stain
In a video interview, Carolyn Kay, MD, discusses the latest ASCCP guidelines and the introduction of dual stain cytology for improved HPV detection and patient management, aiming to alleviate anxiety and enhance efficacy in cervical cancer prevention.
Medical Laboratory Observer
February 26, 2024
Diabetes and heart failure: Understanding the role of cardiac biomarker testing
Laboratories may begin to see an influx of cardiac biomarker tests accompanying HbA1c testing based on updated American Diabetes Association guidelines concerning heart failure in people with diabetes.
Medical Laboratory Observer
February 26, 2024
Closing clinical gaps in cervical cancer
In the past 40 years, the number of cases and deaths from cervical cancer have decreased significantly as more women regularly had Pap tests and with the introduction of human papillomavirus (HPV) testing and the development of HPV vaccines.
Medical Laboratory Observer
November 20, 2023
Actionable answers: Targeted multiplex PCR respiratory testing at the point of care
In the unpredictable post-COVID-19 pandemic era, patient expectations have shifted when it comes to diagnostic testing.
CLP
November 16, 2023
16 Clinical Laboratory Predictions for 2024
Consolidation, legislation, new testing modalities, and a shift to more consumer-driven testing are just some of the clinical laboratory predictions for 2024.
Medscape
November 15, 2023
Blood Test for MS Activity Gets FDA Breakthrough Designation
The US Food and Drug Administration (FDA) has granted breakthrough device designation to the Elecsys Neurofilament Light Chain (NfL) test for multiple sclerosis (MS). Made by Roche, the test is intended to be used as an aid in detection of disease activity in adults aged 18-55 years with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), providing insights for disease management.
CLP
October 17, 2023
Roche Launches Automated Vertical Transportation for Patient Lab Samples
Roche has launched a laboratory conveyor system, the cobas connection modules (CCM) Vertical, for the U.S. market. The elevator and overhead components of its fully automated and modular CCM system are designed to help low-, mid-, and high-volume laboratories optimize space, productivity, and patient care.
NeurologyLive
June 27, 2023
FDA Clears Roche’s Beta-Amyloid and Total-Tau Assays for Alzheimer Assessment
With the approval, Roche has three FDA-cleared tests that are reflective of the main Alzheimer's disease pathologies and help clinicians more completely define the disease biologically.
Medical Laboratory Observer
January 23, 2023
Shifting HIV focus from at-risk populations to at-risk behavior
Since 2015, only about 1.2 million people have been considered ‘at risk’ of HIV and potentially able to benefit from pre-exposure prophylaxis, also known as PrEP, according to medical literature. These numbers were gleaned by focusing on identifiable populations, such as men who have sex with men and drug users who use needles.
Medical Laboratory Observer
September 21, 2022
Breast cancer biomarkers, and a new clinical category for HER2 expression
Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients with lower levels of HER2 expression and potentially open the door to new, targeted, and personalized therapies for many patients.
Medical Laboratory Observer
August 24, 2022
Navigating respiratory disease testing challenges this fall
If respiratory diseases were not complicated enough before COVID-19, this fall may be the example of peak complexity as atypical infectious disease seasons threaten to become the new normal and COVID-19 continues to mutate.